Tolosa P, Garcia-Fructuoso I, Pascual T, Martinez-Saez O, et al. Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. Breast Cancer Res Treat 2026;216:21.
PMID: 41762297